{"id":639,"date":"2026-04-24T21:03:37","date_gmt":"2026-04-24T19:03:37","guid":{"rendered":"https:\/\/studienportal-endometriumkrebs.de\/noggo-en17-duolife\/"},"modified":"2026-07-20T16:51:11","modified_gmt":"2026-07-20T14:51:11","slug":"noggo-en17-duolife","status":"publish","type":"post","link":"https:\/\/studienportal-endometriumkrebs.de\/en\/noggo-en17-duolife\/","title":{"rendered":"NOGGO-EN17 \/ DUOLife"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

DUOLife<\/strong><\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Observational study on first-line therapy in patients with advanced or recurrent endometrial cancer<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

The DUOLife study is a non-interventional observational study. This means that patients receive an already planned or initiated and approved therapy \u2013 no therapies or other interventions are prescribed or adjusted by the study. This study aims solely to collect data on real-world experience from routine treatment in Germany (real-world data): How effective and tolerable is first-line therapy with carboplatin, paclitaxel, and durvalumab, followed by maintenance therapy with durvalumab \u2013 alone or in combination with olaparib \u2013 in patients with advanced or recurrent endometrial cancer (also known as uterine cancer)? <\/p>

What is being investigated in this study?<\/strong><\/h2>

Advanced (FIGO III or IV) or recurrent endometrial cancer is increasingly treated with chemotherapy in combination with immunotherapy. This study investigates how well such a therapy works in routine clinical practice. Large clinical trials have already confirmed the benefit of these therapies in hundreds of patients. Now, the effect is to be investigated outside of large clinical trials in normal routine treatment in Germany. This makes it possible to examine the effect of the therapy even in patients who did not participate in or could not participate in the clinical trials. <\/p>

Durvalumab<\/em> is an immune checkpoint inhibitor. The drug helps the body’s immune system better recognize and fight cancer cells. Many tumor cells are protected from attack by immune cells by a specific protein (PD-L1) on their surface. Durvalumab<\/em> blocks this protective mechanism, allowing the immune system to attack the cancer cells. The combination of chemotherapy and immunotherapy can mutually reinforce each other: chemotherapy can damage tumor cells, making them more \u201cvisible\u201d to the immune system \u2013 and durvalumab<\/em> then helps the immune system fight them more effectively. <\/p>

After chemotherapy, durvalumab<\/em> is continued as maintenance therapy to keep any remaining cancer cells under long-term control and prevent recurrence.<\/p>

Endometrial cancer can have different biological characteristics. An important factor is whether certain repair mechanisms in the tumor cells are functional or not. One of these repair mechanisms is called mismatch repair (MMR).If this repair mechanism does not work, it is referred to as dMMR<\/strong> (deficient mismatch repair). Such tumors often have many genetic changes and frequently respond particularly well to immunotherapies like durvalumab<\/em>.If the repair system functions normally, it is referred to as pMMR<\/strong> (proficient mismatch repair). These tumors are generally less sensitive to immunotherapies, so additional drugs such as olaparib<\/em> are used to enhance the effect. <\/p>

Olaparib<\/em> is a PARP inhibitor, a drug that prevents cancer cells from repairing damage to their DNA. The addition of olaparib<\/em> to durvalumab<\/em> maintenance therapy in pMMR tumors can help better control tumor growth by making cancer cells more susceptible to an immune response. This therapeutic benefit has already been demonstrated in the past, for example, by the DUO-E study.The goal is to achieve the most effective and long-term control of the disease, even in patients with pMMR tumors, through the combined maintenance therapy of durvalumab<\/em> + olaparib<\/em>. <\/p>

What is the aim of the study?<\/strong><\/h2>

The DUOLife study focuses on the question of how long it takes until the next therapy is needed \u2013 a measure called rwTTNT (<\/span>real-world Time to Next Treatment<\/em>). In addition, it also assesses, among other things, how long the disease remains under control (rwPFS = <\/span>real-world progression-free survival<\/em>), what side effects occurred, and how patients are doing in their daily lives (quality of life, symptoms).<\/span><\/p>

What is the study procedure?<\/strong><\/h2>

A total of approximately 150 patients<\/strong> are expected to participate in Germany. All will receive a therapy that is already used in clinical routine \u2013 so it is not a clinical study with experimental treatment. <\/p>

For every patient with endometrial cancer, the tumor’s dMMR or pMMR status is determined at diagnosis. Depending on their diagnosis, patients can be enrolled in one of these two groups: <\/p>